Nuvalent Business Summary

Nuvalent, Inc. (NUVL) is a clinical-stage biopharmaceutical company transitioning to a commercial-stage entity under its "OnTarget 2026" operating plan. The company currently generates revenue primarily through interest income from its substantial cash reserves—estimated at $1.4 billion as of early 2026—while advancing its pipeline toward its first potential FDA product approvals. Its business model centers on the discovery and development of next-generation, structure-based kinase inhibitors designed to overcome treatment resistance and off-target toxicities in genetically defined cancers. Primary business segments are organized around its lead clinical programs: zidesamtinib (NVL-520) for ROS1-positive non-small cell lung cancer (NSCLC), which has a PDUFA date of September 18, 2026, and neladalkib (NVL-655) for ALK-positive NSCLC, with an NDA submission planned for the first half of 2026. Nuvalent competes directly with oncology incumbents Pfizer, Roche, and Bristol Myers Squibb, positioning its candidates as superior alternatives due to their high selectivity and ability to penetrate the central nervous system (CNS) to address brain metastases. Nuvalent was founded by Matthew D. Shair, Ph.D., a Professor of Chemistry and Chemical Biology at Harvard University, whose research in kinase biology forms the company's scientific core. The leadership team is led by Chief Executive Officer James Porter, Ph.D., an oncology veteran who previously directed the development and FDA approval of duvelisib at Infinity Pharmaceuticals. Key technical leadership includes Chief Scientific Officer Henry Pelish, Ph.D., and Chief Development Officer Darlene Noci, both of whom bring extensive experience in medicinal chemistry and clinical strategy. The company is backed by prominent institutional investors including Deerfield Management and Bain Capital Life Sciences. Its Board of Directors features industry heavyweights such as Chairman Anna Protopapas and Ron Squarer, the former CEO of Array BioPharma, reflecting a strategic focus on scaling commercial operations and global delivery.